Molgramostim + sucralfate + hyaloronan is under clinical development by Reponex Pharmaceuticals and currently in Phase II for Venous Leg Ulcers (Crural Ulcer). According to GlobalData, Phase II drugs for Venous Leg Ulcers (Crural Ulcer) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Molgramostim + sucralfate + hyaloronan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Molgramostim + sucralfate + hyaloronan overview
RNX-022 is under development for the treatment of venous leg ulcer (ulcus cruris). It is a combination of molgramostim, sucralfate and hyaluronic acid. The drug combination is administered topically. Molgramostim is recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).
Reponex Pharmaceuticals overview
Reponex Pharmaceuticals, a subsidiary of Pharma Equity Group A/S is a biopharmaceutical company. It offers pharmaceuticals and therapies for chronic diseases. Reponex Pharmaceuticals drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041 and RNX-051. It develops new, effective treatments for acute or life threatening disease, such as bacterial peritonitis and colorectal cancer, or may be chronic diseases that reduce lifespan and the quality of life. The company also provides drug administration platform for local targeted treatments. Reponex Pharmaceuticals is headquartered in Horsholm, Denmark.
For a complete picture of Molgramostim + sucralfate + hyaloronan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
